Literature DB >> 21969814

Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells.

Erin M Bekes1, Elena I Deryugina, Tatyana A Kupriyanova, Ewa Zajac, Kenneth A Botkjaer, Peter A Andreasen, James P Quigley.   

Abstract

Urokinase-type plasminogen activator (uPA) and plasmin have long been implicated in cancer progression. However, the precise contributions of the uPA/plasmin system to specific steps involved in cancer cell dissemination have not been fully established. Herein, we have used a highly disseminating variant of the human PC-3 prostate carcinoma cell line, PC-hi/diss, as a prototype of aggressive carcinomas to investigate the mechanisms whereby pro-uPA activation and uPA-generated plasmin functionally contribute to specific stages of metastasis. The PC-hi/diss cells secrete and activate significant amounts of pro-uPA, leading to efficient generation of plasmin in solution and at the cell surface. In a mouse orthotopic xenograft model, treatment with the specific pro-uPA activation-blocking antibody mAb-112 significantly inhibited local invasion and distant metastasis of the PC-hi/diss cells. To mechanistically examine the uPA/plasmin-mediated aspects of tumor cell dissemination, the anti-pro-uPA mAb-112 and the potent serine protease inhibitor, aprotinin, were used in parallel in a number of in vivo assays modeling various rate-limiting steps in early metastatic spread. Our findings demonstrate that, by generating plasmin, activated tumor-derived uPA facilitates early stages of PC-hi/diss dissemination, specifically the escape from the primary tumor and tumor cell intravasation. Moreover, through a series of in vitro and in vivo analyses, we suggest that PC-hi/diss-invasive escape and dissemination may be enhanced by cleavage of stromal fibronectin by uPA-generated plasmin. Together, our findings point to inhibition of pro-uPA activation at the apex of the uPA/plasmin cascade as a therapy-valid approach to control onset of tumor escape and ensuing metastatic spread.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21969814      PMCID: PMC3182273          DOI: 10.1593/neo.11704

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  53 in total

1.  The RGD story: a personal account.

Authors:  Erkki Ruoslahti
Journal:  Matrix Biol       Date:  2003-11       Impact factor: 11.583

2.  Limited cleavage of cellular fibronectin by plasminogen activator purified from transformed cells.

Authors:  J P Quigley; L I Gold; R Schwimmer; L M Sullivan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

3.  The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.

Authors:  Niels Behrendt; Karin List; Peter A Andreasen; Keld Danø
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

Review 4.  The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy.

Authors:  Nicolai Sidenius; Francesco Blasi
Journal:  Cancer Metastasis Rev       Date:  2003 Jun-Sep       Impact factor: 9.264

5.  High-dose aprotinin reduces blood loss in patients undergoing total hip replacement surgery.

Authors:  M Janssens; J Joris; J L David; R Lemaire; M Lamy
Journal:  Anesthesiology       Date:  1994-01       Impact factor: 7.892

6.  Characterisation of a novel series of aprotinin-derived anticoagulants. I. In vitro and pharmacological properties.

Authors:  J M Stassen; A M Lambeir; G Matthyssens; W C Ripka; A Nyström; J J Sixma; J Vermylen
Journal:  Thromb Haemost       Date:  1995-08       Impact factor: 5.249

Review 7.  Fibronectin and integrins in invasion and metastasis.

Authors:  S K Akiyama; K Olden; K M Yamada
Journal:  Cancer Metastasis Rev       Date:  1995-09       Impact factor: 9.264

8.  Collagenolysis-dependent angiogenesis mediated by matrix metalloproteinase-13 (collagenase-3).

Authors:  Andries Zijlstra; Ronald T Aimes; Dan Zhu; Karine Regazzoni; Tatyana Kupriyanova; Marco Seandel; Elena I Deryugina; James P Quigley
Journal:  J Biol Chem       Date:  2004-04-05       Impact factor: 5.157

9.  Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor.

Authors:  V Ellis; N Behrendt; K Danø
Journal:  J Biol Chem       Date:  1991-07-05       Impact factor: 5.157

10.  An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II.

Authors:  K A Hajjar; A T Jacovina; J Chacko
Journal:  J Biol Chem       Date:  1994-08-19       Impact factor: 5.157

View more
  25 in total

1.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

2.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

Review 3.  Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature.

Authors:  Elena I Deryugina; James P Quigley
Journal:  Matrix Biol       Date:  2015-04-22       Impact factor: 11.583

4.  Rapid detection of urokinase plasminogen activator using flexible paper-based graphene-gold platform.

Authors:  Bipin Sharma; Prakash Parajuli; Ramakrishna Podila
Journal:  Biointerphases       Date:  2020-02-04       Impact factor: 2.456

5.  Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.

Authors:  Kenneth A Botkjaer; Elena I Deryugina; Daniel M Dupont; Henrik Gårdsvoll; Erin M Bekes; Cathrine K Thuesen; Zhuo Chen; Zhou Chen; Michael Ploug; James P Quigley; Peter A Andreasen
Journal:  Mol Cancer Res       Date:  2012-10-04       Impact factor: 5.852

6.  In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated β1 integrin and induction of FAK/PI3K/Akt motility signaling.

Authors:  B Casar; I Rimann; H Kato; S J Shattil; J P Quigley; E I Deryugina
Journal:  Oncogene       Date:  2012-12-03       Impact factor: 9.867

7.  Tumor MMP-1 activates endothelial PAR1 to facilitate vascular intravasation and metastatic dissemination.

Authors:  Anna Juncker-Jensen; Elena I Deryugina; Ivo Rimann; Ewa Zajac; Tatyana A Kupriyanova; Lars H Engelholm; James P Quigley
Journal:  Cancer Res       Date:  2013-05-16       Impact factor: 12.701

8.  Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function.

Authors:  Hua Fang; Veronica R Placencio; Yves A DeClerck
Journal:  J Natl Cancer Inst       Date:  2012-09-13       Impact factor: 13.506

9.  Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

Review 10.  Tumor cell intravasation.

Authors:  Serena P H Chiang; Ramon M Cabrera; Jeffrey E Segall
Journal:  Am J Physiol Cell Physiol       Date:  2016-04-13       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.